DK1003552T3 - LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation - Google Patents

LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation

Info

Publication number
DK1003552T3
DK1003552T3 DK97936112T DK97936112T DK1003552T3 DK 1003552 T3 DK1003552 T3 DK 1003552T3 DK 97936112 T DK97936112 T DK 97936112T DK 97936112 T DK97936112 T DK 97936112T DK 1003552 T3 DK1003552 T3 DK 1003552T3
Authority
DK
Denmark
Prior art keywords
proliferation
cd2a antibody
inhibiting
cell activation
cd2a
Prior art date
Application number
DK97936112T
Other languages
English (en)
Inventor
Herve Bazin
Dominique Latinne
Ruth Kaplan
Thomas Kieber-Emmons
Christina E Postema
Mary E White-Scharf
Original Assignee
Biotransplant Inc
Univ Catholique Louvain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotransplant Inc, Univ Catholique Louvain filed Critical Biotransplant Inc
Application granted granted Critical
Publication of DK1003552T3 publication Critical patent/DK1003552T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK97936112T 1995-06-07 1997-07-18 LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation DK1003552T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/472,281 US5817311A (en) 1993-03-05 1995-06-07 Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
PCT/US1997/012645 WO1999003502A1 (en) 1995-06-07 1997-07-18 LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T CELL ACTIVATION AND PROLIFERATION

Publications (1)

Publication Number Publication Date
DK1003552T3 true DK1003552T3 (da) 2008-08-25

Family

ID=26792646

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97936112T DK1003552T3 (da) 1995-06-07 1997-07-18 LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation

Country Status (9)

Country Link
US (1) US5817311A (da)
EP (1) EP1003552B1 (da)
AT (1) ATE395081T1 (da)
AU (1) AU754185B2 (da)
CA (1) CA2295604C (da)
DE (1) DE69738692D1 (da)
DK (1) DK1003552T3 (da)
ES (1) ES2307301T3 (da)
WO (1) WO1999003502A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5951983A (en) * 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US7592006B1 (en) * 1993-03-05 2009-09-22 Université Catholique de Louvain Composition comprising the LO-CD2a antibody
US6849258B1 (en) * 1997-07-18 2005-02-01 Universite Catholique De Louvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
EE200100123A (et) * 1998-08-31 2002-06-17 Biogen, Incorporated CD2 siduva aine kasutamine ja mäluefektor-T-lümfotsüütide populatsioon
WO2000045842A2 (en) * 1999-02-04 2000-08-10 The General Hospital Corporation Methods for human allografting
US6541611B1 (en) * 1999-06-18 2003-04-01 Universite Catholique De Louvain LO-CD2b antibody
PL368556A1 (en) * 2001-02-01 2005-04-04 Biogen, Inc. Methods for treating or preventing skin disorders using cd2-binding agents
AU2002250236A1 (en) * 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
CA2439852A1 (en) * 2001-03-02 2002-09-12 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
WO2003009740A2 (en) * 2001-07-24 2003-02-06 Biogen Idec Ma Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
JP2006508638A (ja) 2002-05-22 2006-03-16 エスバテック・アーゲー 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
WO2005077018A2 (en) * 2004-02-06 2005-08-25 Astellas Us Llc Methods of treating skin disorders
MXPA06012744A (es) * 2004-05-04 2007-02-19 Genaissance Pharmaceutical Inc Marcadores de haplotipo y metodos para utilizarlos en la determinacion de la respuesta al tratamiento.
CA2565259A1 (en) * 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
CN105708862B (zh) * 2008-09-02 2020-11-06 普拉里斯坦有限公司 来自胎盘组织的粘附细胞及其在治疗中的用途
CN119857155A (zh) 2017-11-29 2025-04-22 海德堡医药研究有限责任公司 用于耗尽cd5+细胞的组合物和方法
NZ781538A (en) 2019-04-24 2025-12-19 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
KR20220051164A (ko) 2019-07-05 2022-04-26 아이오엠엑스 테라퓨틱스 아게 Igsf11 (vsig3)의 항체 결합 igc2 및 이의 용도
EP4175668A1 (en) 2020-07-06 2023-05-10 iOmx Therapeutics AG Antibodies binding igv of igsf11 (vsig3) and uses thereof
US20240228620A1 (en) 2022-10-06 2024-07-11 Bicara Therapeutics Inc. Multispecific proteins and related methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO1991001752A1 (en) * 1989-07-27 1991-02-21 Fred Hutchinson Cancer Research Center Immunosuppressive monoclonal antibodies, hybridomas and methods of transplantation
US5283058A (en) * 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
US5858725A (en) * 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
ES2164699T3 (es) * 1993-03-05 2002-03-01 Univ Catholique Louvain Anticuerpo lo-cd2a y usos del mismo para inhibir la activacion y la proliferacion de las celulas t.

Also Published As

Publication number Publication date
AU3886297A (en) 1999-02-10
AU754185B2 (en) 2002-11-07
CA2295604C (en) 2008-09-30
WO1999003502A1 (en) 1999-01-28
ATE395081T1 (de) 2008-05-15
ES2307301T3 (es) 2008-11-16
HK1025738A1 (en) 2000-11-24
EP1003552B1 (en) 2008-05-14
EP1003552A4 (en) 2002-10-02
EP1003552A1 (en) 2000-05-31
CA2295604A1 (en) 1999-01-28
US5817311A (en) 1998-10-06
DE69738692D1 (de) 2008-06-26

Similar Documents

Publication Publication Date Title
DK1003552T3 (da) LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation
DK0859957T3 (da) Patientspecifikke immunadsorbenser til ekstraporal apherese og fremgangsmåde til deres fremstilling
DK0741784T3 (da) Ligand (ACT-4-L) til en receptor på overfladen af aktiverede CD4+ T-celler
DK0735893T3 (da) PAN DR-bindende peptider til styrkelse af immunsvaret
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
ES2084338T3 (es) Anticuerpos recombinantes especificos para el tnf alfa.
CA2429027A1 (en) Antibodies against human receptor h4-1bb
ATE155043T1 (de) Behandlung von autoimmun- und entzundungskrankheiten
DK0900380T3 (da) Fremgangsmåde til udvælgelse og fremstilling af T-celle-peptid-epitoper og vacciner indeholdende disse udvalgte epitoper
ATE132197T1 (de) Monoklonale antikörper
DK0687300T3 (da) LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation
EP0313378A3 (en) Methods and compositions for transient elimination of humoral immune antibodies
NO973875D0 (no) Fremgangsmåte for simulering av en immunrespons
DE60042941D1 (de) Verwendung von anti-cd3 monoklonale antikörper und il-5 zur behandlung von autoimmunkrankheiten
NO922621D0 (no) Farmasoeytiske preparater inneholdende antigen-antistoffkomplekser og anvendelser derav
WO2000078814A3 (en) LO-CD2b ANTIBODY AND USES THEREOF FOR INHIBITING T CELL ACTIVATION AND PROLIFERATION
PT959899E (pt) Anticorpo lo-cd2a e suas utilizações para inibir a activação e proliferação de células t
DK1021196T3 (da) Anvendelse af en kemisk stabiliseret chloritoplösning til inhibering af en antigenspecifik immunreaktion
DE69839943D1 (de) Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen
NO972522L (no) Monoklonale antistoffer med immunoundertrykkende aktivitet
DK0852623T3 (da) Nukleinsyremolekyler kodende for proteiner, som medierer adhæsionen af Neisseria-celler til humane celler
ATE245661T1 (de) Natürliche menschliche igm antikörper
KR910006478A (ko) 인체 트립타제 유사 단백질
ATE209041T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung